IFITM2 and mantle cell lymphoma: This finding is supported by a recent study in which Lee et al. discovered that deletion of IFITM3 in MCL cells reduced competitive fitness and proliferation, and the upregulation of IFITM2 might suggest a compensation mechanism for the loss of IFITM327.